Emerging Treatment Options for Advanced-Stage Mycosis Fungoides

Abstract

A 72-year-old man with a 3-year history of hypersensitivity skin reaction managed with topical steroids and ultraviolet B (UVB) radiation develops skin tumors chiefly involving his face. After a diagnosis of stage IIB mycosis fungoides (MF), he begins oral low-dose weekly methotrexate with partial response lasting 5 months. Subsequently, he receives six cycles of weekly gemcitabine and achieves a partial response with resolution of skin tumors but persistence of scattered patches and plaques ( Fig 1 ). He begins daily bexarotene and interferon alfa (IFN-α) three times per week while continuing topical steroids. When scattered patches and plaques progress 7 months later, UVB radiation is added to his regimen. His disease remains well controlled until 17 months later, when he develops pneumonia complicated by pericarditis, requiring discontinuation of IFN-α. Over the next year, he continues bexarotene maintenance therapy and topical steroids but requires localized radiation therapy to isolated patch and tumor lesions. When patch lesions become more extensive, he receives total-skin electron beam therapy (TSEBT). Nearly 4 years after diagnosis of stage IIB MF and 5 months after completion of TSEBT, two tumor lesions redevelop on his face and scalp. The scalp tumor has overlying epidermal change with ulceration; the face tumor is subdermal with minimal overlying epidermal change and obstructs the right external auditory meatus ( Fig 1 D). You consider management options.